TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05824572

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic visit audio recordings for self-management in older adults
Description: The intervention is audio-recordings of primary care clinic visits that are shared with participating patients. All scheduled visits with study clinicians will be recorded and shared with patients randomized to the intervention group (AUDIO) for 12 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: The Usual Care arm participants will receive After Visit Summaries (AVS) per the standard delivery at each institution
Study: NCT06503913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Muscular Therapy
Description: Psychologically informed physiotherapy which integrates training to reduce overactivity of postural muscles which can interfere with the mechanics of breathing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing visualisation
Description: Breathing visualisation; Data from two 3D camera are combined and used to calculate respiratory volumes. These volumes are then used to drive an animation of breathing so that the patient can understand how their breathing pattern compares to an optimal pattern. Note this is not a medical device as data from this system is only used for education and not for diagnostic or treatment decisions.
Study: NCT06259123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA I&T
Description: 2 cycles of 5 GBq \[177Lu\]Lu-PSMA I\&T at 6-week intervals prior radical prostatectomy for patients with oligometastatic prostate cancer
Study: NCT06411665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine
Description: Patient-controlled intravenous analgesia with oliceridine for up to 3 days after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Patient-controlled intravenous analgesia with morphine for up to 3 days after surgery.
Study: NCT05880238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The intervention consisted of a total of 3 modules, 20 sessions. These modules are: Module A: I explore my inner and outer world Module B: I am learning self-editing methods C module: discovering self-editing In these modules, students were trained to use sensorimotor strategies for self-regulation. The intervention program was carried out in one-hour sessions, twice a week, for a total of 10 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will continue their education according to the preschool education curriculum.
Study: NCT05857293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter-guided PDA stent implantation
Description: PDA stent is the primary treatment for patients with duct-dependent pulmonary circulation. It serves as a temporary bridge for later surgical repair by keeping the duct patent to improve oxygen saturation
Study: NCT05758571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGCG
Description: EGCG (high pressure liquid chromatographic purity ≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day.
Study: NCT05564988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preconditionning
Description: Remote ischemic conditioning will be induced using a Tourniquet cuff applied to the patient's non-dominant arm. The device used will be an Ulrich Kariba machine. A strip of absorbent cotton will be applied to the arm and the tension cuff will be placed over it in a standard way. The systolic pressure and the application time will be set manually.~Ischemia will be obtained after inflating the cuff to a pressure of 200 mmHg (or a pressure at least 50 mmHg above the patient's systolic pressure). After a five-minute period, the cuff will be deflated and the arm allowed to reperfuse for five minutes. These maneuvers will be repeated until 3 cycles of ischemia- reperfusion have been completed once a day. Patients will experiment with this procedure for at least 5 days.
Study: NCT05950113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Receive IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Receive IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Receive IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Receive CART-BCMA/CS1 cells IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT04903028

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Two electrodes on the scalp will be connected to transcutaneous electrical nerve stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS 10 Hz DLPFC
Description: 10 Hz repetitive transcranial magnetic stimulation (rTMS) will be delivered over left dorsolateral prefrontal cortex (DLPFC).
Study: NCT06366282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Counseling for Childhood Traumatic Injury
Description: Caregiver intervention will be provided by the counseling team that includes components of trauma narrative, psychoeducation, coping strategies, and resilience-building using, for burn patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care for Childhood Traumatic Injury
Description: Control group receives the current standard of care provided by the counseling team
Study: NCT05210907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNUH-CD19-CAR-T
Description: SNUH-CD19-CAR-T is an autologous CAR-T from T cells collected from each patient. Administer a single dose of SNUH-CD19-CAR-T to patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukemia, and evaluate safety and efficacy of SNUH-CD19-CAR-T for 12 months after the infusion.
Study: NCT05136287

Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: Patients are included after GLP1 agonists prescription , at the first dispensation
Study: NCT05221710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: The acupuncture treatment will be performed by the technique of lifting, thrusting, twirling and rotating the needle until the patient is being De-qi (getting a numbness or other acupuncture feeling).The needle will be kept in place for approximately 30 minutes. The point of acupuncture is determined by a traditional Chinese medicine doctor.~Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points.~On the basis of the above acupuncture treatment,two points that do not cross the joint will be chosen for electrical stimulation in electroacupuncture group.
Study: NCT06118736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary Medial Hemi-epiphysiodesis of the proximal femur
Description: Temporary Medial Hemi-epiphysiodesis of the proximal femur
Study: NCT05759819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard stenting
Description: The cilostazol-coated BioMimics 3D stent on the delivery system is deployed into the target lesion.
Study: NCT04805177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematoma evacuation
Description: early minimally invasive image guided hematoma evacuation in patients suffering from ICH
Study: NCT05305651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Description: Sotrovimab dose and administration per standard of clinical care
Study: NCT04906343

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Colonoscopy surveillance in SPS patient after 3 years of the last colonoscopy.
Study: NCT04691271

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: After the patient entered the operating room, early SGB will be performed by a designated experienced anesthesiologist using the B-ultrasound visualization technique. The intervention site is the ipsilateral side of the planned craniotomy site. After routine disinfection, 0.5% ropivacaine 8-10 mL will be injected into the surface of the longus colli muscle on the medial side of the prevertebral fascia at the level of the C6 anterior tubercle, and then the puncture point will be covered with sterile dressings. The success criteria of e-SGB are Horner's syndrome, which is characterized by a miosis, ptosis, enophthalmos, conjunctival hyperemia and facial reddishness without sweating. For the camouflaging arm, the anesthesiologist only covered the corresponding part of the patient with sterile dressings to confuse the follow-up, without any puncture. All patients will be admitted to the ICU after the operation and then receive the standard of care.
Study: NCT05996133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 30 mL of 0.25% bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 0.5 mL (5 mg) preservative-free dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 0.1 mL epinephrine 1:400,000.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: 3 mL normal saline
Study: NCT04994743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT113176
Description: CORT113176 lipid capsule formulation for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT113176
Description: CORT113176 lipid capsule formulation for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT113176
Description: CORT113176 lipid capsule formulation for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching CORT113176
Description: Placebo matching CORT113176 lipid capsule formulation for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching CORT113176
Description: Placebo matching CORT113176 lipid capsule formulation for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching CORT113176
Description: Placebo matching CORT113176 lipid capsule formulation for oral administration
Study: NCT06041087

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Exercise
Description: A single bout of high-intensity exercise (cycling intervals, resistance exercise, plyometrics) per trial.
Study: NCT06124404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: After a loading dose of 0.08mg/kg, a maintaining dose of 0.1mg/kg/h is given
Study: NCT04830982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Diazoxide
Description: 500 micromoles added to one liter of cardioplegia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo added to one liter of cardioplegia
Study: NCT06041087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise
Description: A single bout of high-intensity exercise (cycling intervals, resistance exercise, plyometrics) per trial.
Study: NCT05051995

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Open-label placebo
Description: Prior to the open-label placebo administration, an explanation why placebos without concealment might be effective is offered. Participants receive placebo pills with the instruction to take 2 pills daily for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Open-label placebo
Description: Prior to the open-label placebo administration, an explanation why placebos without concealment might be effective is offered. Participants receive placebo pills with the instruction to take 2 pills daily for 2 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No-treatment
Description: During the no-treatment phase, participants receive no treatment for 2 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No-treatment
Description: During the no-treatment phase, participants receive no treatment for 2 weeks.
Study: NCT06142708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual trigger (human chorionic gonadotropin plus GnRH-agonist)
Description: Human chorionic gonadotropin will be added to GnRH-agonist as a dual trigger in participants previously having had a suboptimal response to GnRH-agonist trigger only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH-agonist only trigger
Description: GnRH-agonist only will be used for final maturation
Study: NCT05387070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon PTH
Description: TransCon PTH is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
Study: NCT06041087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise
Description: A single bout of high-intensity exercise (cycling intervals, resistance exercise, plyometrics) per trial.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: High-Intensity Exercise
Description: A single bout of high-intensity exercise (cycling intervals, resistance exercise, plyometrics) per trial.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate (Maltodextrin powder mixed with water)
Description: 50g consumed immediately after exercise and 1h after exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skim Milk
Description: 500ml consumed immediately after exercise and 1h after exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Greek yogurt
Description: 200g consumed immediately after exercise and 1h after exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 500ml consumed immediately after exercise and 1h after exercise.
Study: NCT04622150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized Adherence Enhancement (CAE)
Description: CAE is comprised of a series of up to four treatment modules whose inclusion is determined based upon an individuals reasons for nonadherence (adherence barriers).The standardized modules are Psychoeducation, Modified Motivational Interviewing, Communication with Providers, Medication Routines. CAE participants will have a core series of approximately four sessions spaced about one week apart over a period of 4-6 weeks, and one booster in-person session 4 weeks after the completion of the four core sessions (total of approximately 5 sessions). Sessions 2-4 will be delivered remotely by the study interventionist. All participants will have the first session in-person. The final booster session will be conducted at the sites and will review all previously introduced materials. There will be a follow-up phone call with the study interventionist that will occur in the four-week time period between completion of four CAE core sessions and prior to initiation of the booster CAE session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual (eTAU)
Description: eTAU participants will receive monthly text messages (or phone calls for participants who prefer not to receive texts) to refill medications, fill eCAPs and brief general adherence promotion messages during the follow-up period.
Study: NCT05447013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coronavirus-2-specific T cells
Description: Coronavirus-2-specific T cells ex vivo expanded from selected COVID-19 recovered donors

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care (SOC)
Description: standard of care (SOC)
Study: NCT06092931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC-806
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC-806
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral syrup

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral tablets
Study: NCT05656092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP0612
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP2202
Description: Placebo drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2204
Description: Reference drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPP2201
Description: Placebo drug
Study: NCT06141980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 0.3 mg
Description: DWP16001 0.3mg, Tablets, Orally, Once daily
Study: NCT05015868

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Enrollment of patients afferent to our Center with cryptogenic drug-resistant epilepsy with onset in pediatric age, subject to informed consent;~* acquisition and updating of Electroencephalogram polygraphic data of wakefulness and sleep and neuroradiological data (previous negative brain magnetic resonance imaging);~* execution of a complete neuropsychological assessment for the classification of cognitive aspects and evaluation of executive functions;~* execution of genetic tests through Next generation sequencing epilepsies panel or exome sequencing

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging-Electroencephalogram combined analysis
Description: A functional brain magnetic resonance imaging is executed analysing blood oxygenation level dependent signal.~During the functional recording, a contemporary electroencephalogram is registered in order to analyse the space-time relationship between the epileptic discharges and the bold abnormalities.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High density- electroencephalogram or 7 Tesla magnetic resonance imaging
Description: In the event that neither the cause nor the epileptogenic area has been identified, we will evaluate the execution of further tests, such as:~* execution of High Density-electroencephalogram recording at IRCCS Medea di Conegliano (TV, Italy) (approximately 3 patients / year) for a further electrophysiological definition;~* 7 Tesla brain magnetic resonance imaging performed at IRCCS Stella Maris in Calambrone (PI, italy) (approximately 3 patients / year expected), to obtain greater spatial resolution and better neuroradiological definition.
Study: NCT02484196

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires
Study: NCT04081883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biosensor algorithm
Description: The biosensor DIABLO responses will be compared to the measurements of standard CGMS, using blood glucose measures every 10 minutes by taking interstitial fluid from Diabetes Type 1 (DT1) patients with an internal or external insulin pump.
Study: NCT06049927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine(0.25ml)
Description: 7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine(0.5ml)
Description: 15 ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine(BV)
Description: 7.5μg inactivated influenza antigen (H1N1, H3N2, Victoria) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region. And the immunization schedule is two doses on day 0, 28.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine(BY)
Description: 7.5μg inactivated influenza antigen (H1N1, H3N2, and Yamagata) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses vaccine on day 0, 28.
Study: NCT06637254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31858
Description: HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 48-week treatment period in patients with bronchial asthma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31858
Description: HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 48-week treatment period in patients with bronchial asthma

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the placebo comparator of study